横浜市立大学大学院 医学研究科 幹細胞免疫制御内科学血液・リウマチ・感染症内科

MENU

業績

2023年

膠原病グループ

原著論文: 症例報告を含む

  1. Adachi S, Kirino Y, Higashitani K, et al: Targeting enhanced cell death represents a potential therapeutic strategy for VEXAS syndrome. Rheumatol Adv Pract. 8: rkae065, 2024.
  2. Fukuda N, Kanai D, Hoshino K, et al: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome presenting as recurrent aseptic peritonitis in a patient receiving peritoneal dialysis: a case report. BMC Nephrol. 2024 Jan 11;25(1):18.
  3. Hirahara L, Kirino Y, Soejima Y, et al: Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Behçet disease: a prospective registry study. Front Immunol. 15: 1354969, 2024.
  4. Hirahara Y, Yamaguchi M, Takase-Minegishi K, et al: Pregnancy outcomes in patients with familial Mediterranean fever: systematic review and meta-analysis. Rheumatology (Oxford). 63: 277-284, 2024.
  5. Hirohata S, Kikuchi H, Sawada T, et al: Effect of Infliximab on Chronic Progressive Neuro-Behçet’s Disease: Influence of the Timing of Introduction on the Patient Outcome. Intern Med. 2024;63(4):481-486.
  6. Ichikawa K, Ohno S, Kubo S, et al: Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma. BMJ Case Rep, 17(5): e255958, 2024.
  7. Ichinose K, Sato S, Igawa T, et al: Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry-a historical cohort study. Arthritis Res Ther. 26: 48, 2024.
  8. Kashino K, Tsuchida N, Maeda A, et al: VEXAS syndrome initially presenting as relapsing polychondritis and progressing into neutrophilic dermatosis with systemic symptoms over a 5-year period. Int J Dermatol. 2024.
  9. Katayama Y, Miyawaki Y, Shidahara K, et al: Association between discontinuity of care and patient trust in the usual rheumatologist among patients with systemic lupus erythematosus: a cross-sectional study. Arthritis Res Ther. 26: 195, 2024.
  10. Kirino Y, Maeda A, Asano T, et al: Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry. Rheumatology (Oxford). 2024.
  11. Maeda A, Tsuchida N, Uchiyama Y, et al: Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome. Rheumatology (Oxford). 63: 2056-2064, 2024.
  12. Marton A, Saffari SE, Rauh M, Sun RN, et al: Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure. J Am Coll Cardiol. 83(15): 1386-1398, 2024. doi: 10.1016/j.jacc.2024.02.020.
  13. Misaki K, Tamura N, Azuma T, et al: Associations of disease duration and anti-citrullinated peptide antibody status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis: Post-hoc analysis of a multicentre, real-world observational study in Japan (ORIGAMI). Mod Rheumatol. 34: 297-306, 2024.
  14. Nose Y, Onishi A, Nishimura K, Yamamoto Y, Sada KE, Ichinose K, Yoshimi R, Ohno S, Yanai R, Kajiyama H, Sato S, Shimojima Y, Fujiwara M, Kida T, Miyawaki Y, Matsuo Y, Tsuji H, Morinobu A, Saegusa J.: Rheumatology (Oxford), Online ahead of print, 2024.
  15. Oguro N, Yajima N, Ishikawa Y, et al: Effect of attending rheumatologists’ Big 5 personality traits on patient trust in patients with systemic lupus erythematosus: the TRUMP2-SLE project. J Rheumatol. 51: 168-175, 2024.
  16. Onishi T, Sada K, Hayashi K, et al: Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA). Arthritis Res Ther. 26(1): 198, 2024.
  17. Sakurai N, Yoshimi R, Yajima N, et al: Characteristic features of late-onset systemic lupus erythematosus: An observational study of data from the Lupus Registry of Nationwide Institutions. Lupus. 33: 1306-1316, 2024.
  18. Shirahama Y, Kokuzawa A, Yamauchi Y, et al: Cluster analysis defines four groups of Japanese patients with adult-onset Still’s disease. Mod Rheumatol. 2024;34(6):1213-1220.
  19. Takamatsu R, Shimojima Y, Kishida D, et al: Headache in systemic lupus erythematosus: The LUNA registry cross-sectional study. Lupus. 33: 901-909, 2024.
  20. Teshigawara T, Meguro A, Takeuchi M, et al: Replication Study of the Association of GAS6 and PROS1 Polymorphisms with Behçet’s Disease in a Japanese Population. Ocul Immunol Inflamm. 2024;32(4):447-453.
  21. Yazawa I, Yoshida Y, Yoshimi R, et al: Immature functional development of lumbar locomotor networks in adult Irf8-/- mice. Front Neurosci. 17: 1234215, 2024.
  22. Yoshimi R, Yajima N, Hidekawa C, et al: Effect of shared decision-making on trust in physicians in the management of systemic lupus erythematosus: The Trust Measurement for Physicians and Patients With Systemic Lupus Erythematosus Prospective Cohort Study. Arthritis Care Res (Hoboken). 76: 1597-1605, 2024.
  23. 市川健斗: 感染症を繰り返し治療に難渋したTAFRO症候群の一例. 関東リウマチ. 56. 97-100. 2024.

検索 ページトップへ